Related Experiment Video
Updated: Aug 29, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Neoadjuvant endocrine therapy as a drug development strategy
1Washington University School of Medicine, St. Louis, Missouri, USA. mellis@im.wustl.edu
Abstract:
The aromatase inhibitors offer both toxicity and efficacy advantages over tamoxifen, but to date, their overall impact on breast cancer outcomes has been modest. Advanced breast cancer remains incurable, and for early stage disease, an improvement in survival with AI versus tamoxifen has yet to be demonstrated. Resistance to endocrine manipulation is at the core of the problem and must be overcome to make additional progress. A number of signal transduction inhibitors (STIs) are now under development as endocrine resistance modulators, including those targeting cyclooxygenase-2, HER1 and/or 2 kinase, mTOR, and farnesyl transferase. Developing STIs for this indication is a challenge, however, because we still do not have a clear understanding of the molecular basis of resistance. A complete understanding could translate into a series of endocrine therapy/STI combinations that would be tailored according to the biology of the individual tumor to achieve optimal efficacy and safety. The development of this strategy will require the ability to diagnose resistance mechanisms on a tumor-by-tumor basis, and this can only be attained through careful clinical investigation. Neoadjuvant endocrine therapy is an appealing context to conduct research in this area because clinical outcomes can be obtained within a few months of treatment, and repeated tumor sampling for biomarker analysis (pharmacodynamic tumor profiling) can be readily achieved. However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies.
Insights
Aromatase inhibitors show promise for breast cancer but modest outcomes due to resistance. New signal transduction inhibitors (STIs) are being developed to overcome endocrine resistance and improve patient survival.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Aromatase inhibitors (AIs) offer toxicity and efficacy benefits over tamoxifen for breast cancer treatment, but their overall impact on patient outcomes remains modest.
- Endocrine resistance is a significant challenge in treating advanced breast cancer, hindering further progress.
- Current research focuses on developing signal transduction inhibitors (STIs) to modulate endocrine resistance.
Purpose of the Study:
- To explore the potential of signal transduction inhibitors (STIs) in overcoming endocrine resistance in breast cancer.
- To investigate the development of tailored endocrine therapy/STI combinations based on individual tumor biology.
- To highlight the need for clinical investigations to understand resistance mechanisms and optimize treatment strategies.
Main Methods:
- Review of current and developing signal transduction inhibitors (STIs) targeting pathways like cyclooxygenase-2, HER1/2 kinase, mTOR, and farnesyl transferase.
- Discussion of the challenges in developing STIs due to an incomplete understanding of resistance mechanisms.
- Proposal of neoadjuvant endocrine therapy as a model for clinical investigation, enabling rapid outcome assessment and biomarker analysis (pharmacodynamic tumor profiling).
Main Results:
- Aromatase inhibitors have shown modest improvements in breast cancer outcomes compared to tamoxifen.
- Resistance to endocrine manipulation is a critical barrier to improving survival rates.
- Several signal transduction inhibitors (STIs) are under development as potential modulators of endocrine resistance.
Conclusions:
- Overcoming endocrine resistance is crucial for advancing breast cancer treatment.
- Understanding the molecular basis of resistance is essential for developing effective endocrine therapy/STI combinations.
- Neoadjuvant endocrine therapy provides a valuable platform for clinical research into resistance mechanisms and therapeutic strategies, though optimal approaches require further definition.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Preclinical Development: Overview
01:26Drug Discovery: Overview
01:11Clinical Trials: Overview